Phaseline

Companies › Forma Therapeutics

Forma Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Hematology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Etavopivat
Pyruvate kinase isozymes R/L activator
PKLRPhase 3Sickle Cell DiseaseMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04624659EtavopivatPhase 3Sickle Cell DiseaseHematologyMar 2027
NCT05953584EtavopivatPhase 2Sickle Cell DiseaseHematologyAug 2027
NCT06198712EtavopivatPhase 2Sickle Cell DiseaseHematologyFeb 2028

Targets

PKLR (1)

Companies with the same targets

Agios Pharmaceuticals ScinnoHub Pharmaceutical Novo Nordisk

Companies built like this

Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Wuhan Createrna Science and Technology Pharmanutra

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.